Pharvaris (NASDAQ:PHVS - Get Free Report)'s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $14.90, but opened at $14.52. Pharvaris shares last traded at $15.03, with a volume of 5,780 shares.
Analyst Ratings Changes
Separately, JMP Securities upped their price objective on Pharvaris from $46.00 to $55.00 and gave the company a "market outperform" rating in a report on Friday, January 31st.
Read Our Latest Research Report on Pharvaris
Pharvaris Trading Down 1.1 %
The stock has a market capitalization of $770.75 million, a P/E ratio of -5.26 and a beta of -3.02. The business has a fifty day simple moving average of $17.32 and a 200 day simple moving average of $19.18.
Institutional Investors Weigh In On Pharvaris
Institutional investors and hedge funds have recently bought and sold shares of the stock. FMR LLC lifted its position in shares of Pharvaris by 3.6% during the fourth quarter. FMR LLC now owns 5,395,370 shares of the company's stock valued at $103,429,000 after purchasing an additional 189,714 shares in the last quarter. Soleus Capital Management L.P. lifted its holdings in shares of Pharvaris by 36.2% in the fourth quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company's stock worth $15,617,000 after buying an additional 216,483 shares in the last quarter. Octagon Capital Advisors LP grew its position in Pharvaris by 25.4% in the fourth quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company's stock worth $14,914,000 after acquiring an additional 157,530 shares in the last quarter. Rock Springs Capital Management LP boosted its position in Pharvaris by 2.4% during the 4th quarter. Rock Springs Capital Management LP now owns 775,131 shares of the company's stock valued at $14,859,000 after buying an additional 18,200 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its holdings in Pharvaris by 36.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company's stock worth $8,510,000 after acquiring an additional 118,408 shares during the last quarter.
About Pharvaris
(
Get Free Report)
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
